Literature DB >> 1351804

Analgesic oral efficacy of tramadol hydrochloride in postoperative pain.

A Sunshine1, N Z Olson, I Zighelboim, A DeCastro, F L Minn.   

Abstract

Tramadol hydrochloride is a synthetic opiate agonist with a plasma elimination half-life of 5 to 6 hours and peak plasma levels at about 1 1/2 hours. It derives its activity from attachment to the mu-receptor and blockage of norepinephrine reuptake. The purpose of this single-dose, double-blind, placebo-controlled study was to determine the analgesic effectiveness of an oral administration of two dose levels of tramadol hydrochloride (75 or 150 mg) compared with the combination of 650 mg acetaminophen plus 100 mg propoxyphene napsylate in 161 patients with severe postoperative pain after cesarean section. Analgesia was assessed over a 6-hour period. Treatments were compared on the basis of standard scales for pain intensity and relief and a number of derived variables based on these data. A global rating of the study medication was also used to compare treatments. The three active treatments were effective analgesics, statistically superior to placebo for many hourly and summary measures. A dose response was seen between the two tramadol doses, with the 150 mg dose providing significantly greater analgesia over the lower dose. The 75 mg dose of tramadol was generally more effective than the acetaminophen-propoxyphene combination after hour 2, and significantly so for some hourly time points, as well as for the global rating of the medication. The 150 mg dose of tramadol was significantly more effective than the acetaminophen-propoxyphene combination from hour 2 through hour 6 for the sum of pain intensity differences and total pain relief scores, as well as for the global rating of the medication. Tramadol hydrochloride at both dose levels is an effective analgesic agent and at 150 mg is statistically superior to the acetaminophen-propoxyphene combination. No serious adverse effects were observed; however, dizziness was more frequently reported with 150 mg tramadol.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1351804     DOI: 10.1038/clpt.1992.86

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

Review 1.  Dextropropoxyphene: safety and efficacy in older patients.

Authors:  David J Goldstein; Dennis C Turk
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Clinical pharmacology of tramadol.

Authors:  Stefan Grond; Armin Sablotzki
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  A risk-benefit assessment of tramadol in the management of pain.

Authors:  L Radbruch; S Grond; K A Lehmann
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 4.  Tramadol: a review of its use in perioperative pain.

Authors:  L J Scott; C M Perry
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 5.  Pharmacology and clinical experience with tramadol in osteoarthritis.

Authors:  W A Katz
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 6.  Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states.

Authors:  C R Lee; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 7.  New clinical experience with tramadol.

Authors:  A Sunshine
Journal:  Drugs       Date:  1994       Impact factor: 9.546

Review 8.  The pharmacology of tramadol.

Authors:  P Dayer; L Collart; J Desmeules
Journal:  Drugs       Date:  1994       Impact factor: 9.546

Review 9.  Tramadol for the management of acute pain.

Authors:  K A Lehmann
Journal:  Drugs       Date:  1994       Impact factor: 9.546

10.  Efficacy and Safety Assessment of a Novel Once-Daily Tablet Formulation of Tramadol : A Randomised, Controlled Study versus Twice-Daily Tramadol in Patients with Osteoarthritis of the Knee.

Authors:  Gérald Mongin; Vladimir Yakusevich; Adorjan Köpe; Nadezhda Shostak; Eduard Pikhlak; Laszlo Popdán; Judit Simon; Catherine Navarro; Louise Fortier; Sybil Robertson; Sylvie Bouchard
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.